PROGRAM CHAIR
Donna H. Ryan, MD, FTOS, MABOM
Professor Emerita
Pennington Biomedical Research Center
Louisiana State University
Baton Rouge, Louisiana
PROGRAM OVERVIEW
This Educational Snapshot online activity will provide learners with key concepts on the role that obesity plays not only in driving cardiovascular disease (CVD) risk factors, but also in the development of CVD, as well as the immediate need to address overweight and obesity to reduce the risk of adverse CVD outcomes. The activity will explore strategies on how to initiate the conversation about obesity in patients with CVD, the role that newer anti-obesity medications, such as GLP-1 receptor agonists, have in reducing CVD burden and risk of recurrent events, as well as how to incorporate these agents to clinical practice. In addition, learners will be able to access a visually engaging animation that walks through the rationale and evidence for GLP-1 RAs in patients with CVD.
TARGET AUDIENCE
This activity is designed for cardiologists, advanced practice providers, and other healthcare professionals involved in the management of patients with obesity.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Describe the direct and indirect pathophysiological events triggered by obesity that enhance the risk of CVD development
- Explain the efficacy and safety data supporting the therapeutic potential of newer evidence-informed obesity interventions, including GLP-1 RAs, and the guideline recommendations for their use in patients with obesity
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this virtually live activity for a maximum of 0.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the virtually live activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.25 ANCC contact hours.
ACCME INNOVATION PARTNER
Med Learning Group (MLG) is proud to be recognized as an ACCME Innovation Partner, leading the way in simplifying CME for physicians. As an Innovation Partner, MLG will be working with the ACCME by submitting credits directly to CME Passport.
ACCME INNOVATION PARTNER DISCLAIMER
Upon your acceptance in the evaluation and completion of this CME activity, Med Learning Group will share your completion information and certain personal details (eg, name, National Provider Identifier, birthdate MM/DD) with the ACCME for inclusion in your CME Passport transcript and, as applicable, reporting to certifying, licensing, or other regulatory authorities you specify.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Donna H. Ryan, MD | Discloses that she has participated on the Speakers Bureau at Lilly and Novo Nordisk. She has Ownership Interest in Epitomee Medical, Calibrate Health, Roman Health Ventures, and Scientific Intake. She has been a consultant or advisor to Altimmune, AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Biohaven, Calibrate Health, Carmot Therapeutics/Roche, CinRx Pharma, Currax, Epitomee Medical, eMed, Fractyl Health, Lilly, Nestlé Health Science, Novo Nordisk, Pfizer, Regeneron, Scientific Intake, Structure Therapeutics, Source Bioscience, Tenvie Therapeutics, Wondr Health, Zealand Pharma, and has agreed to consult with Kailera Therapeutics. In addition, she is on the Data Monitoring Committee for Lilly, CinRx Pharma, and Rhythm. |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Shpetim Karandrea, PhD, Medical Director for Med Learning Group, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- La Donna Lue Winston, APRN, has nothing to disclose.
- Russie Allen, MM, Accreditation and Outcomes Manager for Med Learning Group, has nothing to disclose.
- Ana Maria Albino, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Jessica Feygin-Samuels, Program Manager for Med Learning Group, has nothing to disclose.
- Kristen Marks, Program Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: December 05, 2025
EXPIRATION DATE: December 05, 2026
Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
